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High-density lipoproteins (HDL) encompass a hetero-
geneous class of lipoproteins in which apolipoprotein
(apoA)-I predominates. Although concentrations of
HDL with apoE are low in humans, apoE in HDL was
found to facilitate efflux of cholesterol from macro-
phages, HDL particle growth and delivery of HDL-cho-
lesterol to the liver (1). Similar to apoA-I, interaction
of apoE with the transmembrane protein ABCA1 leads
to formation of HDL-like particles (2). Of note, secre-
tion of apoE by macrophages is stimulated by
apoA-I representing a positive feedback process to
potentiate the cholesterol-efflux inducing capacity of
extracellular fluid (3). Moreover, apoE-rich HDL2 par-
ticles are efficient cholesterol acceptors via the
ABCG1 pathway in macrophages (4).
Chymase is a neutral serine protease produced by
mast cells and stored in their cytoplasmic secretory
granules. The enzyme has been detected in mast cells
located in the human arterial intima, the site of ath-
erogenesis (5). Upon stimulation, the activated mast
cells exocytose a fraction of their secretory granules.
While histamine is released from the granules, chy-
mase remains tightly bound to the heparin glycos-
aminoglycan chains in the formed ‘‘granule
remnants’’ and remains partially active in the pres-
ence of its physiologic inhibitors found in plasma (6).
Due to its broad substrate specificity, chymase may
act on various protein components of the extracellular
fluid and the pericellular matrices (7). We have found
that chymase is able to efficiently degrade apoA-I and
apoA-IV, and less efficiently apoA-II, as well as other
components of the reverse cholesterol transport pres-
ent in human plasma, such as the phospholipid trans-
fer protein (8).
Given the role of apoE in the reverse cholesterol
transport, we investigated whether mast cell-derived
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chymase is able to degrade apoE in HDL particles.
Because apoE is involved in the development of
hypertriglyceridemia in humans, and circulating apoE
levels have been shown to increase in hypertrigly-
ceridemic (HTG) patients (9), blood samples were
obtained from two HTG subjects (Helsinki University
Hospital) after overnight fasting. Blood was drained
into pre-cooled tubes containing Kabikinase at a final
concentration of 150 IU/mL of blood. Plasma was
obtained by centrifuging blood at 48C for 30 min and
kept at –708C until analyzed. We used as the source
of chymase the granule remnants isolated from rat
serosal mast cells. Importantly, both rat and human
chymase cleave apoA-I in preb-migrating HDL and
generate identical proteolytic patterns (10).
First, we evaluated the ability of granule remnants
to proteolyze HDL in control plasma obtained from
normolipidemic subjects by adding 125I-labeled HDL
to the incubation mixtures and measuring the pro-
duction of 125I-labeled TCA-soluble degradation pro-
ducts. For that, 50% of plasma (i.e., diluted with
buffer) was treated with 30 mg of chymase-containing
granule remnants at 378C for 1 h and 6 h, respectively.
Incubation was stopped by centrifugation at 48C,
10,000 rpm (8900=g) for 5 min to sediment the gra-
nule remnants. Under these conditions chymase
degraded 2.2% and 3.7% of the 125I-labeled apolipo-
proteins present in HDL. Next, we evaluated by West-
ern blotting the distribution of apoE- and apoA-I-
containing lipoproteins (designated as LpE and LpA-I,
respectively) in such incubation mixtures. Figure 1
shows representative results of two-dimensional poly-
acrylamide gradient gel electrophoresis (first and sec-
ond dimension as indicated by arrows) analyses of
LpE (panels A–D) and LpA-I (panels E–H) of plasma
from subject 1 (Table 1) after treatment with chymase.
In the control (non-treated) plasma, apoE was asso-
ciated to particles having either b- or a-electropho-
retic mobility in the first dimension, and various
mobilities in the second dimension reflecting hetero-
geneous particle sizes (panel A). Compatible with
previous findings (11), a-LpE co-migrated with
a-LpA-I (compare panels A and E). Importantly, incu-
bation of plasma for 1 h with mast cell granules was
sufficient to degrade apoE in all HDL subpopulations,
independently of their electrophoretic mobility and
sizes (panel B). Also, practically all of preb1LpA-I par-
ticles, known for their high sensitivity to chymase
degradation (12), were degraded during this short
time of incubation with chymase (panel F). In sharp
contrast, only minor degradation of a-LpA-I by chy-
mase was achieved even after the longest incubation
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Figure 1 ApoE- and apoA-I-containing lipoproteins before and after treatment of plasma with the neutral protease chymase.
Plasma (30 mL) was incubated with chymase for 1 h and 6 h at 378C in the absence or presence of 30 mg of chymase-
containing granule remnants (40 BTEE units) in 60 mL of 5 mM Tris-HCl containing 150 mM NaCl, 1 mM EDTA, pH 7.4.
Incubation was terminated by centrifuging the vials at 10,000 rpm (8900=g) to sediment the granule remnants, and the
supernatant was kept at –708C until analysis. Aliquots (40 mL) of the incubation mixtures were separated by two-dimensional
electrophoresis in the sequence agarose gel electrophoresis™non-denaturing polyacrylamide gradient gel electrophoresis.
After electroblotting to a nitrocellulose membrane, apoE- and apoA-I-containing particles were detected with polyclonal anti-
sera against human apoE or apoA-I and horseradish peroxidase-conjugated second antibodies, as previously described (11).
Table 1 Characteristics of subject 1.
Gender Male
Age, years 67
Total cholesterol, mmol/L 5.6
LDL cholesterol, mmol/L 2.91
HDL cholesterol, mmol/L 0.89
Triglycerides, mmol/L 3.92
Lipid medication None
time (panel H). Similar results were obtained with
plasma of subject 2 (data not shown). The degrada-
tion of apoE in a-migrating HDL found here could
partly explain why chymase strongly impairs the abil-
ity of mature HDL to act as cellular cholesterol accep-
tor, despite that only a low degree of apoA-I
proteolysis is achieved (13).
In addition to mast cells, human atherosclerotic
lesions contain endothelial cells, smooth muscle cells
and inflammatory cells, such as macrophages and T
lymphocytes that also secrete proteases into the
inflammatory intima. Recently, apoA-I breakdown
products and selective preb-HDL degradation have
been found in the circulation of patients with acute
myocardial infarction (14). This finding supports the
notion that extracellular proteolysis may occur in con-
ditions of protease burden likely to be present in the
inflamed intima. Importantly, the gain in resistance of
mast cell-derived chymase against the serpins by its
association with the heparin proteoglycans of the
mast cell granules (6) strongly suggests that chymase
may be one of the intimal proteases capable of
degrading HDL in vivo in the extracellular fluid of the
intima. As HDL particles in human atherosclerotic
lesions are enriched in apoE (15), we conclude that
extracellular proteolysis of apoE-containing HDL is a
novel inhibitory principle that may interfere with the
initiation of reverse cholesterol transport in the ath-
erosclerotic arterial intima.
Acknowledgements
This work was supported by the Sigrid Juselius Foundation
(M.L.-R.) and the Swiss National Fund (A.v.E.). The Wihuri
Research Institute is maintained by the Jenny and Antti
Wihuri Foundation. The authors thank Isabel Schaukal for
excellent technical assistance.
References
1. Mahley RW, Huang Y, Weisgraber KH. Putting cholesterol
in its place: apoE and reverse cholesterol transport. J Clin
Invest 2006;116:1226–9.
2. Vedhachalam C, Narayanaswami V, Neto N, Forte TM,
Phillips MC, Lund-Katz S, et al. The C-terminal lipid-
binding domain of apolipoprotein E is a highly efficient
mediator of ABCA1-dependent cholesterol efflux that pro-
motes the assembly of high-density lipoproteins. Bio-
chemistry 2007;46:2583–93.
3. Kockx M, Rye KA, Gaus K, Quinn CM, Wright J, Sloane T,
et al. Apolipoprotein A-I-stimulated apolipoprotein E
Lee-Rueckert et al.: Chymase degrades apoE from HDL 423
Article in press - uncorrected proof
secretion from human macrophages is independent of
cholesterol efflux. J Biol Chem 2004;279:25966–77.
4. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR. HDL
from CETP-deficient subjects shows enhanced ability to
promote cholesterol efflux from macrophages in an apoE-
and ABCG1-dependent pathway. J Clin Invest 2006;116:
1435–42.
5. Kaartinen M, Penttila¨ A, Kovanen PT. Mast cells of two
types differing in neutral protease composition in the
human aortic intima. Arterioscler Thromb 1994;14:966–
72.
6. Lindstedt L, Lee M, Kovanen PT. Chymase bound to hep-
arin is resistant to its natural inhibitors and capable of
proteolyzing high density lipoproteins in aortic intimal
fluid. Atherosclerosis 2001;155:87–97.
7. Lindstedt KA, Leskinen MJ, Kovanen PT. Proteolysis of the
pericellular matrix: a novel element determining cell sur-
vival and death in the pathogenesis of plaque erosion and
rupture. Arterioscler Thromb Vasc Biol 2004;24:1350–
8.
8. Lee-Rueckert M, Kovanen PT. Mast cell proteases: phy-
siological tools to study functional significance of high
density lipoproteins in the initiation of reverse cholesterol
transport. Atherosclerosis 2006;189:8–18.
9. Huang Y, Liu XQ, Rall SC Jr, Taylor JM, von Eckardstein
A, Assmann G, et al. Overexpression and accumulation of
apolipoprotein E as a cause of hypertriglyceridemia. J Biol
Chem 1998;273:26388–93.
10. Lee M, Kovanen PT, Tedeschi G, Oungre E, Franceschini
G, Calabresi L. Apolipoprotein composition and particle
size affect HDL degradation by chymase: effect on cel-
lular cholesterol efflux. J Lipid Res 2003;44:539–46.
11. Huang Y, von Eckardstein A, Wu S, Assmann G. Effects
of the apolipoprotein E polymorphism on uptake and
transfer of cell-derived cholesterol in plasma. J Clin
Invest 1995;96:2693–701.
12. Lee M, von Eckardstein A, Lindstedt L, Assmann G,
Kovanen PT. Depletion of preb1LpA1 and LpA4 particles
by mast cell chymase reduces cholesterol efflux from
macrophage foam cells induced by plasma. Arterioscler
Thromb Vasc Biol 1999;19:1066–74.
13. Lee-Rueckert M, Vikstedt R, Metso J, Jauhiainen M,
Kovanen PT. Association of cholesteryl ester transfer
protein with HDL particles reduces its proteolytic inacti-
vation by mast cell chymase. J Lipid Res 2007;Nov 8
wEpub ahead of printx.
14. Eberini I, Gianazza E, Breghi L, Klugmann S, Calabresi L,
Gomaraschi M, et al. Apolipoprotein A-I breakdown is
induced by thrombolysis in coronary patients. Ann Med
2007;39:306–11.
15. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle
AN, Cheung MC, et al. Shotgun proteomics implicates
protease inhibition and complement activation in the
antiinflammatory properties of HDL. J Clin Invest 2007;
117:746–56.
